Paratek Pharmaceuticals, Inc. (PRTK) Stock Analysis
DELISTED 2023
What happened to Paratek Pharmaceuticals, Inc. (PRTK) stock?
Paratek Pharmaceuticals, Inc. (PRTK) no longer trades on public markets. It was delisted in September 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Paratek Pharmaceuticals, Inc. (PRTK) trades at $2.23. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for life-threatening diseases and public health threats. Market cap: $128M, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for PRTK: PRTK does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PRTK against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
PRTK: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Paratek Pharmaceuticals, Inc. (PRTK) Healthcare & Pipeline Overview
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in life-saving therapies for severe diseases and public health threats, including its key products NUZYRA and SEYSARA. The company operates through strategic collaborations and licensing agreements within the competitive biotechnology sector.
What Is the Investment Thesis for PRTK?
Paratek Pharmaceuticals, Inc. presents a focused investment opportunity within the biotechnology sector, driven by its commercial-stage products NUZYRA and SEYSARA. The company's gross margin of 84.7% indicates strong pricing power and efficient cost management. Growth catalysts include ongoing collaborations with Zai Lab and Allergan, as well as the BARDA contract for NUZYRA's development in treating pulmonary anthrax. These partnerships provide revenue streams and potential for expanded market access. However, the company's negative profit margin of -42.2% highlights profitability challenges. Potential risks include competition from established pharmaceutical companies, regulatory hurdles, and the need for continued investment in research and development. Investors should closely monitor the company's ability to achieve profitability and manage its debt effectively.
Based on FMP financials and quantitative analysis
PRTK Key Highlights
NUZYRA is a key product, a once-daily antibiotic approved for treating community-acquired bacterial pneumonia and acute bacterial skin infections.
- SEYSARA is a tetracycline-derived antibiotic for treating moderate to severe acne vulgaris.
- Gross margin stands at 84.7%, indicating strong pricing power and efficient cost management.
- Partnerships with Zai Lab and Allergan enhance global reach and development capabilities.
- Contract with Biomedical Advanced Research and Development Authority (BARDA) supports NUZYRA's development for treating pulmonary anthrax.
Who Are PRTK's Competitors?
PRTK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PRTK's Key Strengths?
Commercial-stage products with established market presence.
- Strategic partnerships with Zai Lab and Allergan.
- Contract with BARDA for NUZYRA development.
- High gross margin of 84.7%.
What Are PRTK's Weaknesses?
Negative profit margin of -42.2%.
- Reliance on a limited number of products.
- High research and development costs.
- Competition from established pharmaceutical companies.
What Could Drive PRTK Stock Higher?
Continued commercialization of NUZYRA and SEYSARA.
- Progress in the BARDA contract for NUZYRA's development in treating pulmonary anthrax.
- Potential expansion of NUZYRA's approved indications.
- Strategic partnerships and licensing agreements.
What Are the Key Risks for PRTK?
Financial-distress signal — its Altman Z-Score of -9.70 sits in the distress zone (elevated bankruptcy risk).
- Competition from established pharmaceutical companies.
- Regulatory hurdles and approval delays.
- Adverse events or safety concerns related to products.
- Negative profit margin and need for improved profitability.
What Are the Growth Opportunities for PRTK?
- Expansion of NUZYRA's Indications: Paratek has the opportunity to expand NUZYRA's approved indications beyond community-acquired bacterial pneumonia and acute bacterial skin infections. This could include pursuing approvals for additional types of bacterial infections, potentially increasing its market reach and revenue. The timeline for such expansions would depend on clinical trial results and regulatory approvals, but could yield significant returns within the next 3-5 years.
- Government Contracts and Stockpiling: The contract with BARDA to develop NUZYRA for pulmonary anthrax represents a significant growth opportunity. Government stockpiling of antibiotics for biodefense purposes could provide a stable revenue stream for NUZYRA. The ongoing threat of bioterrorism and the need for preparedness could drive continued investment in this area, offering long-term growth potential.
- Strategic Partnerships and Licensing Agreements: Paratek can leverage strategic partnerships and licensing agreements to expand its product portfolio and geographic reach. Collaborations with companies like Zai Lab and Allergan demonstrate the potential for these partnerships to drive revenue growth and market access. Future partnerships could focus on developing and commercializing new therapies in related therapeutic areas.
- Commercialization of SEYSARA: SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris, represents a growth opportunity within the dermatology market. Effective marketing and distribution strategies, combined with positive clinical outcomes, could drive increased adoption of SEYSARA among dermatologists and patients. The acne treatment market is substantial, providing ample room for growth.
- Addressing Antibiotic Resistance: With the increasing global threat of antibiotic resistance, Paratek has the opportunity to develop and commercialize novel antibiotics that can overcome resistance mechanisms. This could involve developing new formulations of existing drugs or discovering entirely new classes of antibiotics. Success in this area would position Paratek as a leader in the fight against antibiotic resistance.
What Are PRTK's Competitive Advantages?
- Proprietary drug formulations with patent protection.
- Established relationships with healthcare providers and distributors.
- Strategic partnerships with pharmaceutical companies.
- Government contracts for biodefense applications.
What Does PRTK Do?
Founded in 1996 and headquartered in Boston, Massachusetts, Paratek Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of life-saving therapies. The company addresses life-threatening diseases and other significant public health threats, catering to civilian, government, and military needs. Paratek's lead product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic approved for treating adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Another key product is SEYSARA (sarecycline), a tetracycline-derived antibiotic designed for the treatment of moderate to severe acne vulgaris. Paratek operates through strategic collaborations and licensing agreements. These include partnerships with Zai Lab (Shanghai) Co., Ltd. and Allergan plc, enhancing its global reach and development capabilities. A license agreement with Tufts University supports the development of products for preventing or treating bacterial or microbial diseases. The company also holds a contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of NUZYRA for treating pulmonary anthrax. Additionally, Paratek has a license agreement with Tetraphase Pharmaceuticals, Inc. for XERAVA, used in treating complicated intra-abdominal infections. Paratek continues to focus on addressing unmet medical needs through innovative therapies and strategic partnerships.
What Products and Services Does PRTK Offer?
- Develop and commercialize life-saving therapies for life-threatening diseases.
- Focus on treatments for public health threats for civilian, government, and military use.
- Offer NUZYRA, a broad-spectrum antibiotic for community-acquired bacterial pneumonia and skin infections.
- Provide SEYSARA, a tetracycline for treating moderate to severe acne vulgaris.
- Engage in license and collaboration agreements to expand product reach.
- Develop NUZYRA for pulmonary anthrax treatment through a contract with BARDA.
How Does PRTK Make Money?
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of NUZYRA and SEYSARA.
- Establish partnerships and licensing agreements for product development and distribution.
- Secure government contracts for biodefense-related therapies.
What Industry Does PRTK Operate In?
Paratek Pharmaceuticals, Inc. operates within the competitive biotechnology industry, which is characterized by rapid innovation, stringent regulatory requirements, and high research and development costs. The acne vulgaris treatment market, targeted by SEYSARA, also presents growth opportunities. Paratek's success depends on its ability to navigate regulatory pathways, secure market access, and differentiate its products from competitors.
Who Are PRTK's Key Customers?
- Adult patients with community-acquired bacterial pneumonia.
- Adult patients with acute bacterial skin and skin structure infections.
- Patients with moderate to severe acne vulgaris.
- Government agencies requiring biodefense therapies.
How Paratek Pharmaceuticals, Inc. Is Valued
Paratek Pharmaceuticals, Inc. carries a market capitalization of $128M, placing it in the micro-cap category.
Company Profile
Paratek Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Evan Loh FACC, FAHA,. PRTK has traded publicly since 2009.
Key Financial Metrics
Return on equity for Paratek Pharmaceuticals, Inc. stands at 42.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -36.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -51.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -52.4%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Paratek Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -9.70 places it in the distress zone, a signal of elevated financial risk.
PRTK Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in Paratek's growth potential, suggesting that executives believe in the company's future.
- Community sentiment has shifted positively with recent announcements about new partnerships, enhancing market perception.
- The ongoing development of innovative antibiotic therapies has garnered attention, positioning Paratek as a leader in a critical healthcare segment.
- Increased media coverage around antibiotic resistance has raised awareness of Paratek's products, potentially driving future demand.
Bear Case
- Concerns over the competitive landscape in the pharmaceutical sector have been voiced, with analysts highlighting risks from larger players.
- Community discussions reflect skepticism about the sustainability of Paratek's revenue streams, given the volatile nature of pharmaceutical approvals.
- Recent clinical trial results have raised questions about the effectiveness of their key products, impacting investor confidence.
- Market perception remains cautious due to the company's history of financial instability, leading some investors to adopt a bearish outlook.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PRTK Latest News
No recent news available for PRTK.
Leadership: Evan Loh FACC, FAHA,
Chief Executive Officer
Evan Loh is the Chief Executive Officer of Paratek Pharmaceuticals, Inc. He is a Fellow of the American College of Cardiology (FACC) and the American Heart Association (FAHA). His background includes extensive experience in the pharmaceutical industry, with a focus on clinical development and commercialization of novel therapies. He has held leadership positions at various biotechnology and pharmaceutical companies, contributing to the development of numerous successful products.
Track Record: Under Evan Loh's leadership, Paratek has achieved key milestones, including the FDA approval and commercial launch of NUZYRA and SEYSARA. He has also overseen the establishment of strategic partnerships and the securing of government contracts, positioning the company for future growth. His strategic decisions have focused on expanding the company's product portfolio and geographic reach.
Paratek Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What happened to Paratek Pharmaceuticals, Inc. (PRTK) stock?
Paratek Pharmaceuticals, Inc. (PRTK) no longer trades on public markets. It was delisted in September 2023. The figures below are historical and are not a current quote.
Can I still buy PRTK shares?
No. PRTK stopped trading on public markets in September 2023, so the shares are not available through a broker. Anything you see quoted for PRTK elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PRTK stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Paratek Pharmaceuticals, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Paratek Pharmaceuticals, Inc. do?
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing life-saving therapies for life-threatening diseases and public health threats. Its key products include NUZYRA, a broad-spectrum antibiotic for community-acquired bacterial pneumonia and acute bacterial skin infections, and SEYSARA, a tetracycline-derived antibiotic for treating moderate to severe acne vulgaris. The company operates through strategic collaborations and licensing agreements to expand its product reach and development capabilities.
What do analysts say about PRTK stock?
Analyst coverage of Paratek Pharmaceuticals, Inc. typically focuses on the commercial potential of NUZYRA and SEYSARA, as well as the company's strategic partnerships and government contracts. Key valuation metrics include revenue growth, gross margin, and profitability. Analysts also consider the risks associated with regulatory approvals, competition, and the need for continued investment in research and development. Consensus estimates and price targets vary depending on individual analysts' assessments of these factors.
What are the main risks for PRTK?
The main risks for Paratek Pharmaceuticals, Inc. include competition from established pharmaceutical companies, regulatory hurdles and approval delays, potential adverse events or safety concerns related to its products, and the company's negative profit margin.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Financial metrics are as of the latest available reporting period.